Adverse Cardiovascular Outcomes Among Older Adults With Primary Hyperparathyroidism Treated With Parathyroidectomy Versus Nonoperative Management.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
pmc-release:
01
08
2024
medline:
12
7
2023
pubmed:
26
8
2022
entrez:
25
8
2022
Statut:
ppublish
Résumé
The authors sought to compare the incidence of adverse cardiovascular (CV) events in older adults with primary hyperparathyroidism (PHPT) treated with parathyroidectomy versus nonoperative management. PHPT is a common endocrine disorder that is associated with increased CV mortality, but it is not known whether parathyroidectomy reduces the incidence of adverse CV events. The authors conducted a population-based, longitudinal cohort study of Medicare beneficiaries diagnosed with PHPT (2006-2017). Multivariable, inverse probability weighted Cox proportional hazards regression was used to determine the associations of parathyroidectomy with major adverse cardiovascular events (MACEs), CV disease-related hospitalization, and CV hospitalization-associated mortality. The authors identified 210,206 beneficiaries diagnosed with PHPT from 2006 to 2017. Among 63,136 (30.0%) treated with parathyroidectomy and 147,070 (70.0%) managed nonoperatively within 1 year of diagnosis, the unadjusted incidence of MACE was 10.0% [mean follow-up 59.1 (SD 35.6) months] and 11.5% [mean follow-up 54.1 (SD 34.0) months], respectively. In multivariable analysis, parathyroidectomy was associated with a lower incidence of MACE [hazard ratio (HR): 0.92; 95% confidence interval (95% CI): 0.90-0.94], CV disease-related hospitalization (HR: 0.89; 95% CI: 0.87-0.91), and CV hospitalization-associated mortality (HR: 0.76; 95% CI: 0.71-0.81) compared to nonoperative management. At 10 years, parathyroidectomy was associated with adjusted absolute risk reduction for MACE of 1.7% (95% CI: 1.3%-2.1%), for CV disease-related hospitalization of 2.5% (95% CI: 2.1%-2.9%), and for CV hospitalization-associated mortality of 1.4% (95% CI: 1.2%-1.6%). In this large, population-based cohort study, parathyroidectomy was associated with a lower long-term incidence of adverse CV outcomes when compared with nonoperative management for older adults with PHPT, which is relevant to surgical decision making for patients with a long life expectancy.
Sections du résumé
OBJECTIVE
The authors sought to compare the incidence of adverse cardiovascular (CV) events in older adults with primary hyperparathyroidism (PHPT) treated with parathyroidectomy versus nonoperative management.
BACKGROUND
PHPT is a common endocrine disorder that is associated with increased CV mortality, but it is not known whether parathyroidectomy reduces the incidence of adverse CV events.
METHODS
The authors conducted a population-based, longitudinal cohort study of Medicare beneficiaries diagnosed with PHPT (2006-2017). Multivariable, inverse probability weighted Cox proportional hazards regression was used to determine the associations of parathyroidectomy with major adverse cardiovascular events (MACEs), CV disease-related hospitalization, and CV hospitalization-associated mortality.
RESULTS
The authors identified 210,206 beneficiaries diagnosed with PHPT from 2006 to 2017. Among 63,136 (30.0%) treated with parathyroidectomy and 147,070 (70.0%) managed nonoperatively within 1 year of diagnosis, the unadjusted incidence of MACE was 10.0% [mean follow-up 59.1 (SD 35.6) months] and 11.5% [mean follow-up 54.1 (SD 34.0) months], respectively. In multivariable analysis, parathyroidectomy was associated with a lower incidence of MACE [hazard ratio (HR): 0.92; 95% confidence interval (95% CI): 0.90-0.94], CV disease-related hospitalization (HR: 0.89; 95% CI: 0.87-0.91), and CV hospitalization-associated mortality (HR: 0.76; 95% CI: 0.71-0.81) compared to nonoperative management. At 10 years, parathyroidectomy was associated with adjusted absolute risk reduction for MACE of 1.7% (95% CI: 1.3%-2.1%), for CV disease-related hospitalization of 2.5% (95% CI: 2.1%-2.9%), and for CV hospitalization-associated mortality of 1.4% (95% CI: 1.2%-1.6%).
CONCLUSIONS
In this large, population-based cohort study, parathyroidectomy was associated with a lower long-term incidence of adverse CV outcomes when compared with nonoperative management for older adults with PHPT, which is relevant to surgical decision making for patients with a long life expectancy.
Identifiants
pubmed: 36005546
doi: 10.1097/SLA.0000000000005691
pii: 00000658-202308000-00037
pmc: PMC9968356
mid: NIHMS1830938
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e302-e308Subventions
Organisme : NIA NIH HHS
ID : K76 AG068526
Pays : United States
Organisme : NIA NIH HHS
ID : R03 AG060097
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
C.D.S. reported prior consulting for Virtual Incision Corporation. I.S. reported consulting for Medtronic, Prescient Surgical, and RPWB. T.M. reports employment by Roche following completion of her work on this study. The remaining authors report no conflicts of interest.
Références
Int J Endocrinol. 2011;2011:309068
pubmed: 21403888
Clin Endocrinol (Oxf). 2010 Jul;73(1):30-4
pubmed: 20039887
BMJ. 2003 Sep 6;327(7414):530-4
pubmed: 12958111
J Clin Endocrinol Metab. 2011 Jul;96(7):2112-8
pubmed: 21593116
N Engl J Med. 2018 Jun 28;378(26):2456-2458
pubmed: 29949490
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
J Clin Endocrinol Metab. 2014 Oct;99(10):3561-9
pubmed: 25162665
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Surgery. 2013 Dec;154(6):1394-403; discussion 1403-4
pubmed: 24045156
J Endocrinol Invest. 2009 Jul;32(7):611-6
pubmed: 19574729
Surgery. 2009 Dec;146(6):1042-7
pubmed: 19958931
JAMA Netw Open. 2022 Jun 1;5(6):e2215396
pubmed: 35657624
Nat Rev Endocrinol. 2018 Feb;14(2):115-125
pubmed: 28885621
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
J Clin Endocrinol Metab. 2009 Feb;94(2):335-9
pubmed: 19193908
Am J Med Qual. 2018 Sep/Oct;33(5):493-501
pubmed: 29357679
Epidemiology. 2018 Sep;29(5):e45-e47
pubmed: 29912013
Biometrics. 2005 Dec;61(4):962-73
pubmed: 16401269
Ann Intern Med. 2016 Jun 7;164(11):715-23
pubmed: 27043778
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Clin Endocrinol (Oxf). 2016 Jan;84(1):39-47
pubmed: 26399562
Eur J Endocrinol. 2012 Aug;167(2):277-85
pubmed: 22660025
JAMA Surg. 2016 Oct 1;151(10):959-968
pubmed: 27532368
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
JAMA Surg. 2021 Apr 1;156(4):334-342
pubmed: 33404646
World J Surg. 2003 Feb;27(2):216-22
pubmed: 12616440
JAMA Intern Med. 2022 Jan 1;182(1):10-18
pubmed: 34842909
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3223-3232
pubmed: 30860588
J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1271-1276
pubmed: 30165612
Int J Endocrinol. 2012;2012:408295
pubmed: 22719761
Clin Endocrinol (Oxf). 2015 Dec;83(6):951-6
pubmed: 25393455
J Clin Endocrinol Metab. 2009 Jul;94(7):2255-61
pubmed: 19351725
World J Surg. 1991 May-Jun;15(3):399-405; discussion 406-7
pubmed: 1853620
Surgery. 2005 Jun;137(6):632-8
pubmed: 15933631
Ann Intern Med. 2022 Jun;175(6):812-819
pubmed: 35436153
Int J Cardiol. 2010 Jun 25;142(1):15-21
pubmed: 19117619
J Clin Endocrinol Metab. 2007 Aug;92(8):3114-21
pubmed: 17535997
JAMA Surg. 2020 Jan 1;155(1):32-39
pubmed: 31596437
Atherosclerosis. 2011 Sep;218(1):96-101
pubmed: 21645899